<code id='6897361D6E'></code><style id='6897361D6E'></style>
    • <acronym id='6897361D6E'></acronym>
      <center id='6897361D6E'><center id='6897361D6E'><tfoot id='6897361D6E'></tfoot></center><abbr id='6897361D6E'><dir id='6897361D6E'><tfoot id='6897361D6E'></tfoot><noframes id='6897361D6E'>

    • <optgroup id='6897361D6E'><strike id='6897361D6E'><sup id='6897361D6E'></sup></strike><code id='6897361D6E'></code></optgroup>
        1. <b id='6897361D6E'><label id='6897361D6E'><select id='6897361D6E'><dt id='6897361D6E'><span id='6897361D6E'></span></dt></select></label></b><u id='6897361D6E'></u>
          <i id='6897361D6E'><strike id='6897361D6E'><tt id='6897361D6E'><pre id='6897361D6E'></pre></tt></strike></i>

          Home / explore / hotspot

          hotspot


          hotspot

          author:focus    Page View:5361
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In